3-chloro-5-phenyl-1-prop-2-ynyl-3H-1,4-benzodiazepin-2-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯二氮卓类
• 英文名称: 3-chloro-5-phenyl-1-prop-2-ynyl-3H-1,4-benzodiazepin-2-one
• 化学式: C₁₈H₁₃ClN₂O
• 分子量: 308.8
• InChiKey: YBEUDHFSLIJEEA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  22
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  32.7
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• ORAL DRUG DELIVERY FORMULATIONS
  申请人：Odidi, Isa

  公开号：EP2906202A1

  公开（公告）日：2015-08-19
• [EN] ORAL DRUG DELIVERY FORMULATIONS<br/>[FR] FORMULATIONS DE MÉDICAMENT POUR ADMINISTRATION PAR VOIE ORALE
  申请人：ODIDI ISA

  公开号：WO2014059512A1

  公开（公告）日：2014-04-24

  In an aspect, a formulation is provided that comprises at least one active substance and at least one coat comprising Eudragit E (dimethylaminoethyl methacrylate copolymer), wherein the formulation is free of any active substance external to the coat. The formulation is effective in preventing significant dose dumping in alcoholic/non-alcoholic beverage(s). In another aspect, a formulation is provided that comprises a loading dose having at least one active substance, wherein the release of the at least one active substance shows a Point Of Divergence (POD), in a dissolution profile, with the loading dose representing a point in a timeline where the history of the dissolution or release rate changes from an onset of action to another set of points in the timeline represented by a controlled release. The formulation may be used for releasing up to about 55% of a total dose as a loading dose in order to manage pain.